Zhejiang East-Asia Pharmaceutical (605177.SH) issues a profit warning, expecting a net loss of 95 to 115 million yuan in the fiscal year 2024.
East Asia Pharmaceutical (605177.SH) issues 2024 performance forecast, the company expects to achieve a net profit...
Zhejiang East-Asia Pharmaceutical (605177.SH) released its performance forecast for 2024, projecting a net loss attributable to shareholders of the listed company ranging from 95 million yuan to 115 million yuan. It is expected that the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, will be between 90 million yuan and 110 million yuan in 2024.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
